Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. Hardening of the skin is one of the most visible manifestations of the disease. It’s estimated that about 300,000 Americans have scleroderma. About one third of those people have the systemic form of scleroderma. Since scleroderma presents with symptoms similar to other autoimmune diseases, diagnosis is difficult. This issue will cover: The Genetic Basis of SSc: Genetics, Epigenetics, Mechanisms of Pathogenesis – linking fibrosis, vasculopathy and immune dysregulation, The Role of Autoantibodies in Diagnosis and Prognosis/survival; Managing Raynaud’s phenomenon and ischemic ulcers, managing SSc Lung Disease, Monitoring for and Managing Pulmonary Arterial Hypertension, and many more!
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Copyright-Page - p. 4 5. Contributors - p. 5 6. Forthcoming Issues - p. 7 7. Foreword: Systemic Sclerosis - p. 8 8. Preface: Systemic Sclerosis - p. 9 9. Genetics, Epigenetics, and Genomics of Systemic Sclerosis - p. 10 10. The Pathogenesis of Systemic Sclerosis - p. 18 11. New Classification Criteria for Systemic Sclerosis (Scleroderma) - p. 27 12. Management of Systemic Sclerosis-Related Skin Disease - p. 34 13. Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma - p. 40 14. Management of Systemic-Sclerosis-Associated Interstitial Lung Disease - p. 50 15. Systemic Sclerosis - p. 60 16. Scleroderma Renal Crisis - p. 68 17. Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis - p. 76 18. Musculoskeletal Manifestations of Systemic Sclerosis - p. 86 19. Psychosocial Aspects of Scleroderma - p. 93 20. Index - p. 99
No hay muestra disponible
No hay ficha técnica disponible
Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. Hardening of the skin is one of the most visible manifestations of the disease. It’s estimated that about 300,000 Americans have scleroderma. About one third of those people have the systemic form of scleroderma. Since scleroderma presents with symptoms similar to other autoimmune diseases, diagnosis is difficult. This issue will cover: The Genetic Basis of SSc: Genetics, Epigenetics, Mechanisms of Pathogenesis – linking fibrosis, vasculopathy and immune dysregulation, The Role of Autoantibodies in Diagnosis and Prognosis/survival; Managing Raynaud’s phenomenon and ischemic ulcers, managing SSc Lung Disease, Monitoring for and Managing Pulmonary Arterial Hypertension, and many more!
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Copyright-Page - p. 4 5. Contributors - p. 5 6. Forthcoming Issues - p. 7 7. Foreword: Systemic Sclerosis - p. 8 8. Preface: Systemic Sclerosis - p. 9 9. Genetics, Epigenetics, and Genomics of Systemic Sclerosis - p. 10 10. The Pathogenesis of Systemic Sclerosis - p. 18 11. New Classification Criteria for Systemic Sclerosis (Scleroderma) - p. 27 12. Management of Systemic Sclerosis-Related Skin Disease - p. 34 13. Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma - p. 40 14. Management of Systemic-Sclerosis-Associated Interstitial Lung Disease - p. 50 15. Systemic Sclerosis - p. 60 16. Scleroderma Renal Crisis - p. 68 17. Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis - p. 76 18. Musculoskeletal Manifestations of Systemic Sclerosis - p. 86 19. Psychosocial Aspects of Scleroderma - p. 93 20. Index - p. 99
No hay muestra disponible
No hay ficha técnica disponible
